TOP 30 PE FIRMS REPORT

NEWSLETTER

Like this article?

Sign up to our free newsletter

Marathon Asset Management acquires Kaléo

Marathon Asset Management is to acquires Kaléo, a privately held pharmaceutical company based in Richmond, Virginia, by funds managed by Marathon.  

The total base purchase price is approximately USD310 million in cash, less certain adjustments, and includes potential net revenue-based milestone payments of up to approximately $70 million in cash for the 2022 and 2023 fiscal years, in a transaction that will provide liquidity for Kaléo shareholders upon closing. This new ownership structure will accelerate Kaléo’s growth serving patients at risk for anaphylaxis and other serious and life-threatening conditions.  

“The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” says Dr Evan Bedil, Head of Healthcare at Marathon. “We plan to leverage the company’s strong portfolio of intellectual property, its leading reputation among allergists and its experienced management team, to pursue multiple avenues of growth in the coming years.”

An industry leader in human factors engineering and drug-device combination product development and manufacturing, Kaléo has developed the patented Aerio Auto-Injection Platform which can deliver a wide range of formulation volumes and viscosities to meet the growing unmet needs of the pharmaceutical industry. 

“Kaléo’s executive management team enthusiastically looks forward to joining forces with Marathon, which has been a strong ally of Kaléo as a lender for many years,” says Ronald Gunn, President and CEO of Kaléo. “With its vast resources and well-established capital base, we have found the strongest possible partner to help us commercialise our significant intellectual property and write the next chapter in Kaléo’s story.”

Kaléo is best known for the development and commercialisation of the AUVI-Q (epinephrine injection, USP) 0.15 mg and 0.3 mg, as well as AUVI-q (epinephrine injection, USP) 0.1 mg, the first and only FDA approved epinephrine auto-injector designed for infants and toddlers weighing from 16.5 to 33 pounds. 

“The acquisition of Kaléo represents a strategic investment for our healthcare franchise,” says Randy Raisman, Managing Director, in Marathon Asset Management’s Capital Solutions Group. “We believe that Kaléo has solid growth prospects driven by co-development opportunities, expected market share gains through expanded market access, and growth in awareness among patients.”

The Kaléo Board of Directors unanimously approved the transaction and approval by the requisite shareholders has been obtained. Subject to regulatory clearances, closing is expected to take place on or prior to 31 December, 2021.

Marathon received legal advice for the transaction from Covington & Burling LLP and Leason Ellis LLP. Morgan Stanley & Co. LLC acted as financial advisor and Hunton Andrews Kurth LLP acted as legal counsel to Kaléo.

Kaléo will remain headquartered in Richmond, Virginia. 

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Features

Talk to Us

What would you like to talk with us about? *